Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.